WO2004043460A1 - Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees - Google Patents

Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees Download PDF

Info

Publication number
WO2004043460A1
WO2004043460A1 PCT/US2003/036039 US0336039W WO2004043460A1 WO 2004043460 A1 WO2004043460 A1 WO 2004043460A1 US 0336039 W US0336039 W US 0336039W WO 2004043460 A1 WO2004043460 A1 WO 2004043460A1
Authority
WO
WIPO (PCT)
Prior art keywords
mammal
pain
composition
effective amount
comprises administering
Prior art date
Application number
PCT/US2003/036039
Other languages
English (en)
Inventor
Nicolas G. Bazan
Carlos Sunkel
Julio Alvarez Builla
Dennis Paul
Original Assignee
Lsu Medical Center Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lsu Medical Center Foundation filed Critical Lsu Medical Center Foundation
Priority to JP2004552114A priority Critical patent/JP2006508137A/ja
Priority to EP03789740A priority patent/EP1572204B1/fr
Priority to AU2003294259A priority patent/AU2003294259B2/en
Priority to DE60327466T priority patent/DE60327466D1/de
Priority to AT03789740T priority patent/ATE429913T1/de
Priority to CA002509252A priority patent/CA2509252A1/fr
Publication of WO2004043460A1 publication Critical patent/WO2004043460A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to analgesic compositions for enhancing the efficacy and/or potency of certain opioid and non- opioid analgesics, that do not suppress blood coagulation, and have little hepatotoxic effect. More particularly, the present 10 invention relates to analgesic compositions that include analgesics referred to as the SCP series (SCP-1 through SCP-5) in combination with opioid and non-opioid analgesics.
  • SCP series SCP-1 through SCP-5
  • Drug combinations such as acetaminophen with codeine (Tylenol III) or acetaminophen with oxycodone (Lortab) produce analgesia that is additive or synergistic.
  • the rational for using such combinations is to reduce the dose of each analgesic, and thus reduce adverse effects and toxicity, while retaining or
  • acetaminophen has equal potency and efficacy to acetylsalicylic acid (aspirin) .
  • acetylsalicylic acid aspirin
  • NAPQI N-acetyl- benzoquinoneimine
  • acetaminophen and a centrally acting analgesic may be even more dangerous than acetaminophen alone.
  • these combinations require higher doses to produce the same analgesic effect because of an increase in tolerance.
  • the safety of the drug decreases as the higher doses of the acetaminophen component increase hepatic and renal toxicity.
  • n is a number from 1 to 5.
  • the analgesic profiles of the SCP series are at least as good as that of acetaminophen. As expected, both types of drugs show little or no activity in the tail-flick and hotplate tests when compared with codeine.
  • SCP-1 is more potent in the abdominal stretch, formalin, and Freund's adjuvant-induced inflammation assays of analgesia than acetaminophen. SCP-1 is lower in toxicity, and, of even greater importance, lower in hepatotoxicity (Paul et al . , 1998). All of these properties make SCP-1 and related derivatives potentially very useful pharmacologic agents.
  • Figure 1 shows the analgesic effect of SCP-1 compared to codeine and acetaminophen.
  • Figure 2 shows an isobologram for acetaminophen and codeine compared to an isobologram for SCP-1 and codeine.
  • Figure 3 shows the hepatotoxicity of SCP-1 alone and in combination with codeine compared to acetaminophen alone and in combination with codeine in C57/bl6 mice.
  • Analgesics by definition include drugs that through their action on the nervous system reduce or abolish the perception of pain without producing unconsciousness.
  • analgesics fall into two broad categories: (1) simple, non-narcotic analgesics, such as aspirin, which appear to work by inhibition of prostaglandin synthetase, and (2) narcotic analgesics, which appear to work through interaction with the endorphin/enkephalin receptor system of the central nervous system.
  • the term "narcotic" has historically been associated with the strong opioid analgesics, but the term is not very useful in a pharmacological context.
  • narcotic analgesics can be further divided into two groups, the opioids and non- opioids .
  • opioids refers to drugs with morphine like activity (agonists and antagonists) , acting on mu, delta and kappa receptors.
  • non-opioids refers to drugs that act via a different mechanism.
  • the drugs that comprise the group known as the opioid analgesics include among others the phenanthrene alkaloids of opium, comprising morphine, codeine, and thebaine. While thebaine produces no analgesia, it is an important intermediate in the production of semisynthetic opioids.
  • agents with structures and function related to morphine include: (1) the morphine analogs, such as hydromorphone, oxymorphone, hydrocodone, and oxycodone; (2) Diels-Alder adducts, such as etorphine and buprenorphine; (3) the morphinan derivatives, such as dextromethorphan and butorphanol ; (4) the benzomorphan derivatives, such as phenazocine, pentazocine and cyclazocine; (5) the piperidine derivatives, such as meperidine and anileridine; and (6) open chain analgesics (methadone type compounds), such as methadone and propoxyphene .
  • the morphine analogs such as hydromorphone, oxymorphone, hydrocodone, and oxycodone
  • Diels-Alder adducts such as etorphine and buprenorphine
  • the morphinan derivatives such as dextromethorphan and butor
  • the drugs that comprise the group known as the non-opioid analgesics include: (1) N-methyl-D-aspartate (NMDA) receptor antagonists, such as dextromethorphan and ketamine and other antagonists that suppress central sensitization by competing for any of the binding site subcategories associated with the NMDA receptor, e.g., the glycine binding site, the phenylcyclidine (PCP) binding site, etc., as well as the NMDA channel; (2) alpha 2 adrenoreceptor agonists, such as clonidine, metomidine, detomidine, dexmetomidine, dexmedetomidine and xylazine, that reduce the release of norepinephrine; (3) other agents, such as tramadol, often mistakenly referred to as an opioid, that produce analgesia by their inhibitory actions on monoamine re-uptake rather than by agonist effect; (4) non-steroidal anti-inflammatory drugs such as
  • Opioid and non-opioid analgesics may cause a variety of side effects including sedation, constipation, hypotension, nausea, vomiting, elevation of cerebrospinal fluid pressure, respiratory depression, physical dependence and tolerance. Therefore, there is a serious need to develop combinations of drugs that supplement the activity of the opioid and non-opioid analgesics, which allows the use of smaller doses of the opioid and non- opioid analgesics.
  • One way of achieving this result is to enhance the analgesic activity of a known opioid or non-opioid analgesic by the addition of a second non-narcotic analgesic.
  • the SCP series are non-narcotic analgesics that have little hepatotoxic effect .
  • the compounds in this series do not produce the metabolite that is responsible for acetaminophen toxicity. As a result, they are more useful than acetaminophen and other non-narcotic analgesics in the treatment of chronic pain.
  • the SCP series does not suppress blood coagulation. Children, the elderly and liver-compromised patients would also benefit from the administration of SCP for the treatment of pain.
  • Pharmaceutical combinations utilizing the SCP series with opioid and non-opioid analgesics has been found to provide enhanced analgesia, without suppressing blood coagulation, and without the toxicity associated with conventional non-narcotic analgesics.
  • the pharmaceutical combinations of the present invention comprise an opioid or a non-opioid analgesic in an intimate admixture with an analgesic from the SCP series along with a pharmaceutically acceptable carrier prepared according to conventional pharmaceutical techniques.
  • Pharmaceutically acceptable carriers include solid or liquid fillers, diluents, and encapsulating substances .
  • the amount of the carrier employed in conjunction with the combination is sufficient to provide a practical quantity of material per unit dose of analgesic.
  • Pharmaceutically acceptable carriers for oral administration include, sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water.
  • Pharmaceutically acceptable carriers for parenteral administration include isotonic saline, propylene glycol, ethyl oleate, pyrrolidone, aqueous ethanol, sesame oil, corn oil, and combinations thereof.
  • Various oral dosages forms can be employed, including solid forms such as tablets, capsules, granules and bulk powders. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
  • Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, and reconstituted solutions and/or suspensions.
  • Pharmaceutically effective combinations can contain between 0.1 and 1000 mg of an analgesic from the SCP series.
  • the preferred pharmaceutically effective combinations contain between 400 and 1000 mg of an analgesic from the SCP series.
  • the pharmaceutically effective amounts of the opioid and non-opioid analgesics in combination with analgesics in the SCP series are similar to the corresponding combinations of opioid and non- opioid analgesics with acetaminophen.
  • the following examples are illustrative of pharmaceutically effective combinations of the present invention:
  • Dosage of SCP 100 - 1000
  • Dosage of Codeine (mg) : 0.1 - 100
  • Preferred Ratios for Oral Dosage (mg codeine : mg SCP) : 15 : 450
  • Dosage of SCP 100 - 1000
  • Dosage of Morphine (mg) : 0.1 - 100
  • Preferred Ratios for Oral Dosage (mg morphine : mg SCP) : 15 450 30 450 60 450
  • Example 3 Hydrocodone Dosage of SCP (mg) : 100 - 1000 Dosage of Hydrocodone (mg) : 0.1 - 100 Preferred Ratios for Oral Dosage (mg hydrocodone : mg SCP) 2.5 450
  • Example 6 Controlled Release Oxycodone Dosage of SCP (mg) : 100 - 1000 Dosage of Oxycodone (mg) : 0.1 - 100 Preferred Weight Ratios for Oral Dosage (mg oxycodone : mg SCP) : 10 900 20 900 40 900 60 900
  • Example 7 Meperidine
  • Dosage of SCP 100 - 1000
  • Dosage of Fentanyl (meg) : 0.1 - 500
  • Preferred Ratios for Oral Dosage (meg fentanyl : mg SCP) : 10 450 50 450
  • Example 14 Sufentanyl Dosage of SCP (mg) 100 - 1000 Dosage of Sufentanyl (meg) : 0.1 - 500 Preferred Ratios for Oral Dosage (meg sufentanyl : mg SCP) : 10 450 50 450
  • Example 15 Remifentanyl Dosage of SCP (mg) : 100 - 1000 Dosage of Remifentanyl (meg) : 0.1 - 500
  • Example 16 Levomethadyl Dosage of SCP (mg) : 100 - 1000 Dosage of Levomethadyl (mg) : 0.1 - 200 Preferred Ratios for Oral Dosage (mg levomethadyl : mg SCP) : 10 : 450
  • Dosage of SCP 100 - 1000
  • Dosage of Methadone (mg) : 0.1 - 200
  • Preferred Ratios for Oral Dosage (mg methadone : mg SCP) : 5 450 10 450 40 450
  • Preferred Weight Ratios for Inj ectable Delivery (methadone : SCP) : 1 100
  • Example 18 Buprenorphine Dosage of SCP (mg) : 100 1000 Dosage of Buprenorphine (mg) : 0.01 100 Preferred Ratios for Oral Dosage
  • Dosage of SCP 100 - 1000
  • Dosage of Dezocine (mg) : 0.1 - 200
  • Preferred Ratios for Oral Dosage (mg dezocine : mg SCP) : 15 450 30 450 60 450
  • Example 21 Nalbuphine Dosage of SCP (mg) : 100 - 1000 Dosage of Nalbuphine (mg) : 0.1 - 200
  • the analgesic potency of SCP-1 is greater than that of acetaminophen in the abdominal stretch assay.
  • the number of stretches exhibited by a mouse after an intraperitoneal (i.p.) injection of dilute acetic acid (Koster et al . , 1959) are counted.
  • the analgesic compounds (acetaminophen, SCP-1, or codeine) were administered orally and fifty-five minutes later, the mice (groups of 8 or more) received an i.p. injection of 10 ml/kg of 0.4% acetic acid.
  • the number of abdominal stretches was counted beginning 5 minutes after the acetic acid injection for a period of 10 minutes. For each of the compounds tested, the percentage of the number of stretches obtained in control animals (29 ⁇ 2.1) was calculated.
  • an isobolographic analysis was performed to demonstrate the synergistic effect of an SCP- l/narcotic analgesic pharmaceutical combination.
  • the isobologram is a quantitative method for measuring interactions between drugs where dose-effect relationships are depicted in a multidimensional array with lines connecting dose pairs that are equieffective in relationship to a common pharmacological endpoint .
  • the isobolographic analysis permits a full range of doses and dose combinations to be examined where the proportion of the first drug to the second actually varies from 0 to infinity, and to determine, by virtue of the graphical display, whether any one or more of the paired drug combinations displays unique pharmacological properties in comparison to the entire body of generated data.
  • the ED 50 for each drug was calculated using nonlinear regression analysis.
  • a combination of acetaminophen and codeine or a combination of SCP-1 and codeine was tested using the same assay.
  • the ratios of acetaminophen to codeine or SCP-1 to codeine were equivalent to the ratios of the ED 50 s of each drug alone.
  • Dose-response curves for the drug combination ratios were produced and ED 50 s calculated.
  • the ED 50 s were graphed according to the method of Tallarida et al . , (1997) . Briefly, the dose of one drug is depicted on the X-axis with a linear scale and a range of 0 to its ED 50 . The dose of the other drug is likewise depicted on the Y-axis. A line is drawn diagonally from ED 50 to ED 50 . This line is known as the line of additivity, as any combination of X and Y doses that fall upon this line would be predicted to produce 50% analgesia.
  • the experimental ED 50 is plotted according to the dose of each individual drug and the standard error oriented on a line from the origin through the data point. Thus, when the ED 50 of the drug combination is plotted, any point (+ standard error) closer to the origin than the line of additivity would be considered to be synergistic
  • the administered doses of acetaminophen and SCP-1 were equivalent to the acetaminophen LD50 in mice (3.7 mmole/kg) and the administered dose of codeine was 50 mg/kg.
  • GPT glutamic/pyruvic transaminase
  • GOT glutamic/oxalacetic transaminase

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des combinaisons pharmaceutiques d'analgésiques opioïdes et non opioïdes, en mélange intime avec un analgésique d'une série de dérivés de 4-hydroxyphénylamines N-acylées, liés par un pont alkylène à l'atome d'azote d'un groupe 1,2-benzisothiazol-3(2H)-one 1,1-dioxyde. L'invention concerne également des méthodes permettant d'utiliser lesdites combinaisons pour alléger la souffrance de mammifères. Lesdits combinaisons analgésiques présentent une capacité analgésique améliorée, n'altèrent pas la coagulation sanguine et ont des effets hépatotoxiques réduits.
PCT/US2003/036039 2002-11-12 2003-11-12 Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees WO2004043460A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2004552114A JP2006508137A (ja) 2002-11-12 2003-11-12 Ｎ−アセチル化４−ヒドロキシフェニラミン誘導体を含む相乗作用性の組み合わせ
EP03789740A EP1572204B1 (fr) 2002-11-12 2003-11-12 Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees
AU2003294259A AU2003294259B2 (en) 2002-11-12 2003-11-12 Synergistic combinations with analgesic properties comprising N-acylated 4-hydroxyphenylamine derivatives
DE60327466T DE60327466D1 (de) 2002-11-12 2003-11-12 Synergistische zusammensetzungen mit analgetischen eigenschaften die eine n-acetylierte 4-hydroxyphenylamine derivate enthalten
AT03789740T ATE429913T1 (de) 2002-11-12 2003-11-12 Synergistische zusammensetzungen mit analgetischen eigenschaften die eine n- acetylierte 4-hydroxyphenylamine derivate enthalten
CA002509252A CA2509252A1 (fr) 2002-11-12 2003-11-12 Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/292,105 US6864271B2 (en) 2002-11-12 2002-11-12 Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
US10/292,105 2002-11-12

Publications (1)

Publication Number Publication Date
WO2004043460A1 true WO2004043460A1 (fr) 2004-05-27

Family

ID=32229373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036039 WO2004043460A1 (fr) 2002-11-12 2003-11-12 Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees

Country Status (9)

Country Link
US (1) US6864271B2 (fr)
EP (2) EP2074996A1 (fr)
JP (1) JP2006508137A (fr)
AT (1) ATE429913T1 (fr)
AU (1) AU2003294259B2 (fr)
CA (1) CA2509252A1 (fr)
DE (1) DE60327466D1 (fr)
ES (1) ES2325369T3 (fr)
WO (1) WO2004043460A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110440A1 (fr) * 2003-06-12 2004-12-23 The Foundation For The Lsu Health Sciences Center Combinaisons synergiques contenant des derives de 4- hydroxyphenylamines n-acylees et cafeine

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754088B2 (en) * 1997-09-04 2002-11-07 Demerx, Inc. Noribogaine in the treatment of pain and drug addiction
US8026266B2 (en) * 2005-11-08 2011-09-27 Arcion Therapeutics, Inc. Treatment of length dependent neuropathy
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
WO2012012764A1 (fr) 2010-07-23 2012-01-26 Demerx, Inc. Compositions de noribogaïne
EP2481740B1 (fr) 2011-01-26 2015-11-04 DemeRx, Inc. Procédés et compositions pour préparer de la noribogaïne à partir de voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (fr) 2011-12-09 2013-06-13 Demerx, Inc. Esters phosphoriques de noribogaïne
US9795559B2 (en) 2011-12-11 2017-10-24 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA2989550C (fr) 2014-06-18 2023-08-08 Demerx, Inc. Derives d'indole et de benzofurane halogenes d'isoquinuclidene et procedes pour leur preparation.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554636A (en) * 1995-04-21 1996-09-10 Lsu Medical Center Foundation N-acylated 4-hydroxphenylamine derivatives with analgesic properties and pharmaceutical compositions containing them
US6127352A (en) * 1988-02-01 2000-10-03 Uribe; Jose R. Pharmaceutical compositions with analgesics containing codeine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562110A (en) * 1896-06-16 Relasting-machine
US554636A (en) * 1896-02-11 Exercising-iviachine
US4681897A (en) 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
KR100243956B1 (ko) * 1991-09-06 2000-03-02 랄프 알. 팔로 트라마돌 물질 및 아세트아미노펜을 포함하는 통증 치료용 약제학적 조성물
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
AU5882298A (en) 1997-01-29 1998-08-18 Chong Kun Dang Corporation New analgesic composition
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
AU2001250646A1 (en) * 2000-04-17 2001-10-30 Yamanouchi Pharmaceutical Co..Ltd. Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127352A (en) * 1988-02-01 2000-10-03 Uribe; Jose R. Pharmaceutical compositions with analgesics containing codeine
US5554636A (en) * 1995-04-21 1996-09-10 Lsu Medical Center Foundation N-acylated 4-hydroxphenylamine derivatives with analgesic properties and pharmaceutical compositions containing them
US5621110A (en) * 1995-04-21 1997-04-15 Lsu Medical Center Foundation Process for preparing N-acylated 4-hydroxypenylamine derivatives with analgesic properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GONZALEZ-MARTIN G ET AL: "Hepatic kinetics of SCP-1 (N-[alpha-(1,2-benzisothiazol-3(2H)-ona-1,1 -dioxide-2-yl)-acetyl]-p-aminophenol ) compared with acetaminophen in isolated rat liver", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 46, no. 3, 1 November 1998 (1998-11-01), pages 293 - 297, XP004257004, ISSN: 0939-6411 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110440A1 (fr) * 2003-06-12 2004-12-23 The Foundation For The Lsu Health Sciences Center Combinaisons synergiques contenant des derives de 4- hydroxyphenylamines n-acylees et cafeine

Also Published As

Publication number Publication date
JP2006508137A (ja) 2006-03-09
DE60327466D1 (de) 2009-06-10
EP1572204B1 (fr) 2009-04-29
US20040092541A1 (en) 2004-05-13
US6864271B2 (en) 2005-03-08
ATE429913T1 (de) 2009-05-15
EP2074996A1 (fr) 2009-07-01
AU2003294259B2 (en) 2008-12-18
AU2003294259A1 (en) 2004-06-03
EP1572204A1 (fr) 2005-09-14
ES2325369T3 (es) 2009-09-02
CA2509252A1 (fr) 2004-05-27

Similar Documents

Publication Publication Date Title
EP1572204B1 (fr) Combinaisons synergiques contenant des derives de 4-hydroxyphenylamines n-acylees
JP2006508137A5 (fr)
US4599342A (en) Pharmaceutical products providing enhanced analgesia
CA2323805C (fr) Association analgesique comprenant des antagonistes des recepteurs nmda et des analgesiques narcotiques
US6054451A (en) Analgesic composition and method for alleviating pain
US5919826A (en) Method of alleviating pain
EP1244447B1 (fr) Nouveaux procedes et nouvelles compositions comprenant des opioides et des antagonistes d'opioides
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
EP1161263A1 (fr) Compositions analgesiques comprenant des composes anti-epileptiques, et leurs procedes d'utilisation
CA2544648A1 (fr) Composes analgesiques, leur synthese, et compositions pharmaceutiques les contenant
EP1635825B1 (fr) Combinaisons synergiques contenant des derives de 4- hydroxyphenylamines n-acylees et de la cafeine
US20030139396A1 (en) Method of treatment
WO2004026291A1 (fr) Formulations orales d'ibuprofene et de tramadol, methodes de preparation de ces dernieres
Miranda et al. Involvement of Adrenergic, Serotonergic, and Opioid Mechanisms in Tramadol-Induced Antinociception in Mice
NZ565416A (en) Therapeutic combination comprising a NMDA receptors blocker and a narcotic analgesic substance
US20050187239A1 (en) Synergistic l-methadone compositions and methods of use thereof
EP1620106A1 (fr) Composition pharmaceutique comprenant un inhibiteur de la cathepsine s et un opioide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004552114

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2509252

Country of ref document: CA

Ref document number: 2003789740

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003294259

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2003789740

Country of ref document: EP